Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
WALTHAM, Mass., Feb. 26, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
-
WALTHAM, Mass., Feb. 2, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
-
Combined Experience Includes Integral Involvement in Development of Multiple Blockbuster Oncology Products, Including Erbitux(r), Tarceva(r) and Taxol(r) WALTHAM, Mass., Jan. 12, 2009 (GLOBE...
-
Company to Receive $12.5 Million Equity Investment WALTHAM, Mass., Dec. 9, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing...
-
Investor and Media Contact: Michelle Edwards, Investor Relations medwards@oxigene.com 415-315-9413 OXiGENE Receives NASDAQ Notification WALTHAM, Mass. -- November 14, 2008 -- OXiGENE, Inc....
-
OXiGENE to Present at Rodman and Renshaw, Lazard Healthcare Conferences WALTHAM, Mass., Nov. 6, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical...
-
OXiGENE Updates Progress and Reports Third Quarter 2008 Financial Results Body: WALTHAM, Mass., Nov. 5, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage,...
-
OXiGENE Announces Third Quarter 2008 Earnings Conference Call and Webcast WALTHAM, MA - October 30, 2008 -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage, biopharmaceutical company...
-
Investor and Media Contact: Michelle Edwards, Investor Relations medwards@oxigene.com ...
-
Investor and Media Contact: Michelle Edwards, Investor Relations medwards@oxigene.com ...